A federally funded UCSD study published in Nature finds CBD reduces alcohol withdrawal and relapse in rodents. Here’s what it means for alcohol treatment and cannabis stocks.

Incannex Healthcare (IXHL) +28% on $20M Buyback‍IXHL surged 28% in a single session after authorizing a $20 million share repurchase program, signaling management’s confidence in the company’s outlook and capital position.‍Rotation Signals: From Tech Titans to Defensive Growth‍This week showcased a market in transition. Nvidia and Palantir (down 20% at one point) dragged the Nasdaq to its worst stretch since April, raising questions about whether the AI trade has peaked—at least temporarily. Palantir, still up over 100% year-to-date, became the poster child of the unwind. Nvidia’s stumble carried similar weight, given its role as the market’s single biggest capex barometer.‍In contrast, money flowed into small caps, healthcare, and consumer staples—areas that had lagged all year but historically shine when the Fed transitions from hiking to easing. Small caps benefit from falling borrowing costs and greater domestic demand sensitivity. Healthcare and staples, meanwhile, provide earnings stability with room for multiple expansion as real yields decline. Industrials and financials also began to stir, hinting at a broader rebalancing beneath the surface.‍Still, the rotation is messy. After Powell’s dovish tone at Jackson Hole, momentum and meme stocks ripped higher into Friday’s close. Opendoor (OPEN), down nearly 20% earlier in the week, finished with a +40% single-day surge, ending deep in the green. The move echoed the retail-driven squeezes of spring, reminding investors that liquidity and speculation haven’t left the system—they’ve just shifted targets.‍Taken together, the tape shows two competing dynamics: a slow migration out of overstretched megacaps toward sectors that historically thrive in easing cycles, and a retail frenzy that continues to chase high-beta growth names. If rate cuts arrive in September, expect the rotation into small caps, healthcare, and cyclicals to deepen—but don’t expect the speculative chase to vanish. The two can coexist, fueling volatility at both ends of the market.‍‍Nvidia Earnings: The AI Boom’s Litmus Test‍The sector rotation narrative now collides with a crucial event: Nvidia’s earnings this Wednesday. After a choppy week where Nvidia logged its sharpest decline since April, the company faces perhaps the most consequential report of the year—not just for itself, but for the entire AI trade.‍Nvidia’s stock has nearly doubled since April, riding the wave of hyperscaler capex pledges from Microsoft, Alphabet, Amazon, and Meta. That surge has left the stock commanding 7.9% of the S&P 500’s weight, meaning any post-earnings swing reverberates through the entire index. Options markets are pricing a ±6% move, which translates to nearly a 0.8% swing in the S&P 500—greater than what traders are bracing for around payrolls or inflation data.‍The stakes are simple: if Nvidia beats and guides higher, the AI bull market may regain its footing after weeks of fatigue. A miss—or even “just fine” results—could puncture the AI premium that has carried the Nasdaq to extremes. In that sense, Nvidia’s report is less about one company and more about whether the AI narrative can still justify record multiples in a market hungry for growth catalysts.‍

FOMC minutes stressed tariffs and inflation, while Powell shifted toward jobs risk.

U.S. debt above $35T forces Fed toward easy money, driving asset price inflation.

Powell scrapped the old Fed framework, opening the door to easing and fueling record Dow highs.

Coffee prices have surged past $4 a pound, driven by drought in Brazil, weak harvests in Vietnam, and a new 50% U.S. tariff. Dutch Bros, Nestlé, and Starbucks are each taking different strategies to weather the squeeze.

AI is transforming healthcare, from imaging and diagnostics to surgical robotics and drug discovery. These U.S.-listed companies represent the top innovators applying AI across the sector.

Harvard University is betting on digital gold, big tech, and classic hedges

SCHD dividend history highlights steady growth, compounding income, and consistency through market cycles.

GEHC stock pushes precision care forward with new MRI, CT, and ultrasound systems, while boosting recurring diagnostic revenue.

What is a good P/E ratio? Find the answer, plus all about the factors that affect company value and different example scenarios.

Markets see Intel as the test case for Washington’s new playbook of direct ownership in strategic industries.